LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development
- Written by PR Newswire
- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities
- Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco
- For people with early Alzheimer's...














